Short-Term Laboratory Outcomes of SGLT2 Inhibitor Use in Type 2 Diabetic Patients: A Retrospective Analysis.

ABSTRACT: Background: This retrospective study evaluated the short-term effects of the SGLT2 inhibitor Dapagliflozin on laboratory markers in patients with type 2 diabetes mellitus (T2DM) over six months. Methods: Data were obtained from electronic health records at the King Abdullah International Medical Research Centre in Riyadh, Saudi Arabia. The study focused on adult T2DM patients who began Dapagliflozin treatment in 2023 or 2024 and underwent laboratory tests before, and six months after, starting treatment, resulting in 783 patients meeting the inclusion criteria. Results: Analysis revealed significant reductions in glycemic markers (p-value < 0.01). Hematological responses revealed divergent trends by sex: females showed increases in mean corpuscular hemoglobin co

SUBMITTER: AlSudais H 

PROVIDER: S-EPMC12653581 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature